This is a summary of the European public assessment report (EPAR) for Pemetrexed medac. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pemetrexed medac. For practical information about using Pemetrexed medac, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Malignant pleural mesothelioma Pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non\-small cell lung cancer Pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non\-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non\-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum\-based chemotherapy. Pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non\-small cell lung cancer other than predominantly squamous cell histology.
Therapeutic Area (MeSH)
ATC Code
L01BA04
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
EMA Name
Pemetrexed medac
Medicine Name
Pemetrexed medac
Aliases
N/ANo risk management plan link.
